Science Corporation
PrivateLast Round
Series C
Mar 5, 2026
Est. Valuation
$1.5B
Total Funding Raised
$541.3M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Science Corporation is a clinical-stage medical technology company that develops advanced brain-computer interface technologies and devices to address critical unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Computing Hardware
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Science Corporation Comparables
Compare Science Corporation with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuralink | 79% | |
| Vivani Medical | 77% | |
| Precision Neuroscience | 77% |
Science Corporation Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 5, 2026 | ||||
| Convertible Debt | Apr 15, 2025 | ||||
| Series B | Nov 22, 2022 | ||||
| Series A | Jul 21, 2021 |
Science Corporation Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Khosla Ventures | Series B, Convertible Debt, Series C |
| Y Combinator | Series B, Series C |
| In-Q-Tel | Series B, Series C |
| Quiet Capital | Series B, Series C |
| Lightspeed Venture Partners | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 38% MoM, reaching 49.2K.
- Apr 13, 2026
Partnered with Card79 on an unspecified project.
Recent news
Latest coverage and updates
- is_developingOct 13, 2026
Science outlines plans in 2021 to develop advanced neural engineering and brain-computer interface technology while working to restore vision for people with visual impairments.
- attends_eventOct 6, 2026
Science attends the EURETINA Congress of European retina specialists in Austria on Oct '26
- is_developingSep 26, 2026
Science is developing a retinal implant aimed at restoring vision
- identified_as_competitor_ofSep 16, 2026
Science identified as competitor of Synchron, Inc.
- attends_eventSep 16, 2026
Science CEO Max Hodak presents a vision for screen-free interfaces at TechCrunch Disrupt 2026 in California on Oct 13th–15th '26.
Science Corporation Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Science Corporation's valuation, stock price, and market status.
Is Science Corporation a public or private company?
Science Corporation is a private company.
What is the current stock price of Science Corporation?
Science Corporation is a private company, so its shares have no public market price. Caplight tracks Science Corporation's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Science Corporation worth (valuation)?
Science Corporation's valuation is estimated at $1.5B based on funding round data.
Can I buy Science Corporation stock?
Science Corporation shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Science Corporation's last funding round?
Science Corporation's most recent funding round was Series C on March 5, 2026.
Who are the main investors in Science Corporation?
Key investors in Science Corporation include Khosla Ventures, Lightspeed Venture Partners.
Will Science Corporation IPO soon?
No public IPO plans have been announced for Science Corporation.
How can I track Science Corporation secondary market activity?
Caplight tracks bids, offers, and trades in Science Corporation's shares on secondary markets.